Randomized, controlled trial of fesoterodine fumarate for overactive bladder in Parkinson's disease

Yonguc T., Sefik E., Inci I., Kusbeci O. Y., Celik S., Aydin M. E., ...More

WORLD JOURNAL OF UROLOGY, vol.38, no.8, pp.2013-2019, 2020 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 38 Issue: 8
  • Publication Date: 2020
  • Doi Number: 10.1007/s00345-019-02981-7
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, BIOSIS, EMBASE, Gender Studies Database, MEDLINE
  • Page Numbers: pp.2013-2019
  • Keywords: Incontinence, Overactive bladder, Fesoterodine fumarate, Cognitive functions, Parkinson's disease, QUALITY-OF-LIFE, URINARY SYMPTOMS, POOLED ANALYSIS, POST-HOC, DYSFUNCTION, PREVALENCE, TOLERABILITY, EFFICACY, OLDER, INCONTINENCE
  • Dokuz Eylül University Affiliated: Yes


Aims To evaluate short-term efficacy and safety of fesoterodine fumarate in Parkinson's disease (PD) patients with overactive bladder (OAB) symptoms. Methods This is a randomized, double-blind, placebo-controlled study. It also has an open-label extension phase. From May 2016 to May 2018, 63 patients were randomized to receive fesoterodine 4 mg or placebo for 4 weeks. At the end of 4 weeks of randomization phase, patients were received fesoterodine fumarate 4 mg daily for another 4 weeks at the open-label extension phase. The change in the mean number of micturition episodes per 24 h period was the primary outcome measure of the study. Results The number of micturition episodes per 24 h period significantly improved with the use of fesoterodine fumarate in the double-blind phase (p < 0.001). Also the mean number of nocturia and urgency episodes decreased in the fesoterodine group. In the open-label phase, the mean number of micturition, urgency and urgency urinary incontinence episodes were improved significantly. The number of nocturia episodes did not change in the open-label phase. Cognitive functions were stable after 4 weeks of fesoterodine 4 mg treatment. Conclusions OAB symptoms were significantly improved in older adults with PD under fesoterodine fumarate treatment, and this advantage continued in the open-label portion in the short term. In this randomized controlled study, the cognitive functions of the participants were not affected by fesoterodine 4 mg treatment compared with placebo.